CA2697795C - Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity - Google Patents

Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity Download PDF

Info

Publication number
CA2697795C
CA2697795C CA2697795A CA2697795A CA2697795C CA 2697795 C CA2697795 C CA 2697795C CA 2697795 A CA2697795 A CA 2697795A CA 2697795 A CA2697795 A CA 2697795A CA 2697795 C CA2697795 C CA 2697795C
Authority
CA
Canada
Prior art keywords
alternatively
group
optionally substituted
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2697795A
Other languages
English (en)
French (fr)
Other versions
CA2697795A1 (en
Inventor
Stephen William Claridge
Ljubomir Isakovic
Michael Mannion
Stephane Raeppel
Oscar Mario Saavedra
Frederic Gaudette
Lijie Zhan
Nancy Z. Zhou
Franck Raeppel
Robert Deziel
Arkadii Vaisburg
Tetsuyuki Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of CA2697795A1 publication Critical patent/CA2697795A1/en
Application granted granted Critical
Publication of CA2697795C publication Critical patent/CA2697795C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2697795A 2007-08-29 2008-08-28 Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity Active CA2697795C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
US60/968,673 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (2)

Publication Number Publication Date
CA2697795A1 CA2697795A1 (en) 2009-03-05
CA2697795C true CA2697795C (en) 2016-08-16

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697795A Active CA2697795C (en) 2007-08-29 2008-08-28 Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN109970759A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588355A (en) * 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
AU2010289353B2 (en) * 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP2013525286A (ja) * 2010-04-16 2013-06-20 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
MX352926B (es) * 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
WO2019182274A1 (en) 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
BR112020023746A2 (pt) 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
EP3819300A4 (en) 2019-09-06 2021-11-24 Wellmarker Bio Co., Ltd. THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
JP2022546861A (ja) * 2019-09-10 2022-11-09 ミラティ セラピューティクス， インコーポレイテッド マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
EP4061421A4 (en) * 2019-11-21 2024-05-15 BeiGene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
JP7434575B2 (ja) * 2020-01-07 2024-02-20 メッドシャイン ディスカバリー インコーポレイテッド 重水素化チエノピリジン系化合物
WO2022060831A1 (en) 2020-09-17 2022-03-24 Mirati Therapeutics, Inc. Combination therapies
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法
CN118846073B (zh) * 2024-06-25 2026-01-30 深圳海王医药科技研究院有限公司 一种酪氨酸激酶抑制剂的新应用
CN121281693B (zh) * 2025-12-08 2026-04-03 中国石油大学(华东) 一种构建稠油重组分平均分子结构的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
DK1382604T3 (da) 2001-04-27 2006-04-18 Kirin Brewery Quinolinderivater med en azolylgruppe og quinazolinderivater
AU2002313249B2 (en) 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7531532B2 (en) 2004-02-27 2009-05-12 Eisai R&D Management Co., Ltd. Pyridine derivative and pyrimidine derivative
US8940896B2 (en) * 2004-03-15 2015-01-27 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2438017T3 (es) * 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物（3）
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
AR060061A1 (es) * 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
JP2010507618A (ja) 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
JP2013525286A (ja) * 2010-04-16 2013-06-20 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤

Also Published As

Publication number Publication date
US20090264440A1 (en) 2009-10-22
BRPI0816064B8 (pt) 2021-05-25
RU2010111729A (ru) 2011-10-10
US20130165477A1 (en) 2013-06-27
CN105777776B (zh) 2021-06-08
US8404846B2 (en) 2013-03-26
PL2183254T3 (pl) 2017-10-31
KR20100075873A (ko) 2010-07-05
WO2009026717A1 (en) 2009-03-05
MX2010002427A (es) 2010-03-30
BRPI0816064A2 (pt) 2015-03-31
BRPI0816064B1 (pt) 2020-01-28
ZA201001512B (en) 2010-11-24
DK2183254T3 (en) 2017-09-11
US8389541B2 (en) 2013-03-05
CN101932586A (zh) 2010-12-29
IL204192A (en) 2016-08-31
CN109970759A (zh) 2019-07-05
RU2495044C2 (ru) 2013-10-10
EP2183254B1 (en) 2017-06-21
KR101556269B1 (ko) 2015-09-30
US20120108628A1 (en) 2012-05-03
AU2008293038B2 (en) 2013-08-29
CN105777776A (zh) 2016-07-20
TW200914458A (en) 2009-04-01
US8846927B2 (en) 2014-09-30
AU2008293038A1 (en) 2009-03-05
CA2697795A1 (en) 2009-03-05
TWI571468B (zh) 2017-02-21
JP2010536887A (ja) 2010-12-02
AR068066A1 (es) 2009-11-04
MY156536A (en) 2016-02-26
ES2635131T3 (es) 2017-10-02
EP2183254A1 (en) 2010-05-12
EP2183254A4 (en) 2011-09-28
JP5656634B2 (ja) 2015-01-21

Similar Documents

Publication Publication Date Title
CA2697795C (en) Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity
AU2009221583B2 (en) Inhibitors of protein tyrosine kinase activity
US20130096136A1 (en) Inhibitors of Protein Tyrosine Kinase Activity
WO2011127567A1 (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130808

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240730

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240730

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702